In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy

Photochemical and Photobiological Sciences

Volumn 7, Issue 3, 2008, Pages 290-298

  Conway, Clare L ^a   Walker, Ian ^a   Bell, Andrea ^a   Roberts, David J H ^a   Brown, Stanley B ^a   Vernon, David I ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE; PHOTOSENSITIZING AGENT; PORPHYRIN; PROTOPORPHYRIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG RETENTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS; UTERINE CERVIX CANCER;

MUS;

EID: 41849127441     PISSN: 1474905X     EISSN: 14749092     Source Type: Journal    
DOI: 10.1039/b715141a     Document Type: Article

References (37)

1. S. B. Brown E. A. Brown I. Walker The present and future role of photodynamic therapy in cancer treatment Lancet Oncol. 2004 5 497 508
2. D. E. Dolmans D. Fukumura R. K. Jain Photodynamic therapy for cancer Nat. Rev. Cancer 2003 3 380 387
3. T. J. Dougherty C. J. Gomer B. W. Henderson G. Jori D. Kessel M. Korbelik J. Moan Q. Peng Photodynamic therapy J. Natl. Cancer Inst. 1998 90 889 905
4. G. Jori C. Fabris M. Soncin S. Ferro O. Coppellotti D. Dei L. Fantetti G. Chiti G. Roncucci Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications Lasers Surg. Med. 2006 38 468 481
5. T. Maisch R. M. Szeimies G. Jori C. Abels L. Madden O. J. Clarke A. Pelegrin J. Greenman R. W. Boyle Antibacterial photodynamic therapy in dermatology Photochem. Photobiol. Sci. 2004 3 907 917
6. R. Hudson R. W. Boyle Strategies for selective delivery of photodynamic sensitisers to biological targets J. Porphyrins Phthalocyanines 2004 8 954 975
7. A. M. Richter E. Waterfield A. K. Jain A. J. Canaan B. A. Allison J. G. Levy Liposomal, delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model Photochem. Photobiol. 1993 57 1000 1006
8. K. Kurohane A. Tominaga K. Sato J. R. North Y. Namba N. Oku Photodynamic therapy targeted to tumor-induced angiogenic vessels Cancer Lett. 2001 167 49 56
9. E. Allemann J. Rousseau N. Brasseur S. V. Kudrevich K. Lewis J. E. van Lier Photodynamic therapy of tumours with hexadecafluoro zinc phthalocynine formulated in PEG-coated poly(lactic acid) nanoparticles Int. J. Cancer 1996 66 821 824
10. N. Swamy D. A. James S. C. Mohr R. N. Hanson R. Ray An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells Bioorg. Med. Chem. 2002 10 3237 3243
11. G. A. van Dongen G. W. Visser M. B. Vrouenraets Photosensitizer-antibody conjugates for detection and therapy of cancer Adv. Drug Deliv. Rev. 2004 56 31 52
12. N. Malatesti K. Smith H. Savoie J. Greenman R. W. Boyle Synthesis, and in vitro investigation of cationic 5,15-diphenyl porphyrin-monoclonal antibody conjugates as targeted photodynamic sensitisers Int. J. Oncol. 2006 28 1561 1569
13. R. Hudson M. Carcenac K. Smith L. Madden O. J. Clarke A. Pelegrin J. Greenman R. W. Boyle The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy Br. J. Cancer 2005 92 1442 1449
14. C. Staneloudi K. A. Smith R. Hudson N. Malatesti H. Savoie R. W. Boyle J. Greenman Development and characterization of novel photosensitizer: scFv conjugates for use in photodynamic therapy of cancer Immunology 2007 120 512 517
15. M. B. Vrouenraets G. W. Visser F. A. Stewart M. Stigter H. Oppelaar P. E. Postmus G. B. Snow G. A van Dongen Development of meta- tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy Cancer Res. 1999 59 1505 1513
16. T. Boehm J. Folkman T. Browder M. S. O'Reilly Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 1997 390 404 407
17. K. Ichikawa T. Hikita N. Maeda S. Yonezawa Y. Takeuchi T. Asai Y. Namba N. Oku Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels Biochim. Biophys. Acta 2005 1669 69 74
18. R. Max R. R. Gerritsen P. T. Nooijen S. L. Goodman A. Sutter U. Keilholz D. J. Ruiter R. M. de Waal Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas Int. J. Cancer 1997 71 320 324
19. P. C. Brooks R. A. Clark D. A. Cheresh Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 1994 264 569 571
20. M. D. Pierschbacher E. Ruoslahti Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule Nature 1984 309 30 33
21. E. Ruoslahti The RGD story: a personal account Matrix Biol. 2003 22 459 465
22. E. Ruoslahti RGD, and other recognition sequences for integrins Annu. Rev. Cell Dev. Biol. 1996 12 697 715
23. M. D. Pierschbacher E. Ruoslahti Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion J. Biol. Chem. 1987 262 17294 17298
24. M. Aumailley M. Gurrath G. Muller J. Calvete R. Timpl H. Kessler Arg-Gly-Asp, constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett. 1991 291 50 54
25. C. F. McCusker P. J. Kocienski F. T. Boyle A. G. Schatzlein Solid-phase synthesis of c(RGDfK) derivatives: on-resin cyclisation and lysine functionalisation Bioorg. Med. Chem. Lett. 2002 12 547 549
26. S. Verrier S. Pallu R. Bareille A. Jonczyk J. Meyer M. Dard J. Amedee Function of linear and cyclic RGD-containing peptides in osteoprogenitor cells adhesion process Biomaterials 2002 23 585 596
27. R. Haubner H. J. Wester Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies Curr. Pharm. Des. 2004 10 1439 1455
28. W. Arap R. Pasqualini E. Ruoslahti Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 1998 279 377 380
29. X. Chen C. Plasencia Y. Hou N. Neamati Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery J. Med. Chem. 2005 48 1098 1106
30. H. M. Ellerby W. Arap L. M. Ellerby R. Kain R. Andrusiak G. D. Rio S. Krajewski C. R. Lombardo R. Rao E. Ruoslahti D. E. Bredesen R. Pasqualini Anti-cancer activity of targeted pro-apoptotic peptides Nat. Med. 1999 5 1032 1038
31. C. Frochot B. D. Stasio R. Vanderesse M. J. Belgy M. Dodeller F. Guillemin M. L. Viriot M. Barberi-Heyob Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity Bioorg. Chem. 2006 35 205 220
32. I. Walker D. I. Vernon S. B. Brown The solid-phase conjugation of purpurin-18 with a synthetic targeting peptide Bioorg. Med. Chem. Lett. 2004 14 441 443
33. N. Chatterjee A. Chatterjee Role of alpha v beta 3 integrin receptor in the invasive potential of human cervical cancer (SiHa) cells J. Environ. Pathol. Toxicol. Oncol. 2001 20 211 221
34. A. J. Schraa R. J. Kok A. D. Berendsen H. E. Moorlag E. J. Bos D. K. Meijer L. F. de Leij G. Molema Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting J. Controlled Release 2002 83 241 251
35. P. Skehan R. Storeng D. Scudiero A. Monks J. McMahon D. Vistica J. T. Warren H. Bokesch S. Kenney M. R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 1990 82 1107 1112
36. Y. OH. Lowry N. J. Rosebrough A. L. Farr R. J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951 193 265 275
37. H. B. Hewitt E. Blake E. H. Proter The effect of lethally irradiated cells on the transplantability of murine tumours Br. J. Cancer 1973 28 123 135